These findings provide new insights into the mechanisms by which tirzepatide leads to clinical improvement in HFpEF
Because these drugs target completely separate biological pathways, they don't chemically interfere with how your body absorbs or processes HRT hormones
Furthermore, as SGLT2 inhibitors are not currently licensed in the UK for reduction of cardiovascular risk when glucose is at target, people will also need to be counselled about off-licence use
Resources: Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries OIG Releases Its Semiannual Report to Congress - July 16, 2026 Meet AAPCs 2025 Chapter of the Year - July 1, 2026 I Am AAPC: Elakiya K, CPC-A, CSM, LSSBB - July 1, 2026
In the first 24 weeks of treatment, some patients experience mild tachycardia (elevated heart rate) as their body adapts to the medication
Open Med (Wars) (2022) 17(1):120315